Tier 2 — API & Excipients Manufacturing

Tier 2 — API & Excipients Manufacturing
Product Description

Tier 2 — API & Excipients Manufacturing▸Opportunity — zero API manufacturing capacity in the entire EAC region; 100% of APIs currently imported.▸Strategic priority — designated by TMDA and PIAT as a medium-to-long-term focus; highest policy priority.▸Investment range — USD 50-200M for scaled API production; enables industrial sovereignty.

Read more Show less

Ministry of Health, The United Republic of Tanzania

  • Country/Region:
    Tanzania, United Republic of
  • Founded:
    1961
  • On CPHI since:
    2026
  • Certificates:
    1
  • Employees:
    5000+
Company types
Other
Primary activities
Other
View company profile
Categories
more categories Show less
Specifications
  • Details
    Tier 2 — API & Excipients Manufacturing▸Opportunity — zero API manufacturing capacity in the entire EAC region; 100% of APIs currently imported.▸Strategic priority — designated by TMDA and PIAT as a medium-to-long-term focus; highest policy priority.▸Investment range — USD 50-200M for scaled API production; enables industrial sovereignty.
  • Selling Points
    Tier 2 — API & Excipients Manufacturing▸Opportunity — zero API manufacturing capacity in the entire EAC region; 100% of APIs currently imported.▸Strategic priority — designated by TMDA and PIAT as a medium-to-long-term focus; highest policy priority.▸Investment range — USD 50-200M for scaled API production; enables industrial sovereignty.
  • Model
    Opportunity — zero API manufacturing capacity in the entire EAC region;
More specifications Fewer specifications

Ministry of Health, The United Republic of Tanzania

  • Country/Region:
    Tanzania, United Republic of
  • Founded:
    1961
  • On CPHI since:
    2026
  • Certificates:
    1
  • Employees:
    5000+
Company types
Other
Primary activities
Other
View company profile

More Products from Ministry of Health, The United Republic of Tanzania (2)

  • Tier 1 — Essential Medicines Manufacturing

    Product Tier 1 — Essential Medicines Manufacturing

    Opportunity — substitute 20-40% of the USD 800M-1B annual import bill. Target WHO-GMP-compliant production of human medicines for infectious and non-infectious diseases including anti-TB, anti-cancer, ARVs, first-line anti-malarials.▸Market assurance — 15% MSD procurement preference; framework agreements; ...
  • Tier 4 — Small Volume Parenterals

    Product Tier 4 — Small Volume Parenterals

    Tier 4 — Small Volume Parenterals▸Opportunity — no ampoules or vials manufacturing in Tanzania. Huge demand across hospitals, immunisation, emergency medicine.▸Investment range — USD 20-60M for a compliant facility.